TELO

Telomir Pharmaceuticals, Inc. (TELO) | Rumor.io

Telomir Pharmaceuticals

TELO

Attention (50-day avg)0%

Attention rank (50-day avg)#3,438

Bullish sentiment (50-day avg)19%

Price to earnings ratio-3.64

Market capitalization82.5M

Earnings per share-1.11

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-10.4M

Social

What share of all stock conversation is about TELO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Apr 30

Telomir Pharmaceuticals' ($TELO) IND for Telomir-Zn in triple-negative breast cancer has been cleared by the FDA, allowing for a Phase 1/2 clinical trial to begin in the first half of 2026.
The trial, TELO-001, will evaluate Telomir-Zn as an oral monotherapy in approximately 76 patients who have previously undergone systemic treatment, focusing on safety, tolerability, and early signs of efficacy.
The company has acquired TELI Pharmaceuticals, establishing global ownership rights to Telomir-1, and has received $1M in funding, aligning with clinical milestones.

Generated by AI

Sentiment

Of the messages about TELO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	66.67% +57.78	64.53% -5.21
Bearish	—	0% 0	33.33% -57.78	35.47% +5.21

Bullish· Nov 21

$TELO is surging pre-market on strong data catalysts, with a key breakout level at $1.43 and a target of $1.50-$2.00.
Telomir Pharmaceuticals has published several high-quality articles in the past five months to build shareholder value, including a recent article about their flagship drug Telomir-1 and its potential for leukemia treatment.
$TELO has a low float and high short interest, making it a potential candidate for a big move when good news is announced, with some speculators predicting a run up to $1.80.

Bearish· Nov 21

The market is treating Telomir Pharmaceuticals with disrespect despite positive news, such as life-saving results for blood cancer.
Short sellers are consistently winning in the market, and the company's positive press releases are often followed by a brief spike and then destruction of the stock price.
The company's recent price action is likely due to dilution, delisting, or reverse splitting, which can be indicative of a scam or fraudulent activity, according to the author.

Generated by AI

Topics

Of the messages about TELO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	73.24%
Analysts	—	—	0%	0.38%
Controversies	—	—	0%	8.58%
Earnings	—	—	0%	0.51%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	17.29%

Announcements· Oct 21

Telomir Pharmaceuticals has executed a binding Letter of Intent (LOI) to acquire TELI Pharma, unifying global rights to Telomir-1 cancer and aging therapy.
The deal positions the company for global market expansion and value growth, with up to $5 million in milestone-tied shareholder contributions.
The acquisition grants Telomir Pharmaceuticals worldwide control of Telomir-1, with a potential $5 million milestone payment, and is seen as a significant upgrade to the company's pipeline.

Technical Analysis· Oct 9

$TELO is breaking down toward $2.05 support after forming a double top near $2.30, with momentum shifting below VWAP and the 9 EMA.
The stock has a strong technical rebound after bouncing off the 0.786 Fib zone near $2.03 and reclaiming 0.618 at $2.13, with a sharp e recovery.
$TELO is showing a potential breakout over $2.20 resistance on the daily chart, with a high volume of 9.5M shares and a low float of 12.97M, setting the stage for volatility.

Generated by AI

Community

Of the messages about TELO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	51.72%	48.36%
Newcomers	—	0%	48.28%	51.64%

Regulars· Oct 9

$TELO is setting up for a strong open after premarket gains, with some analysts highlighting its potential to "go ballistic".
The stock's volume is increasing, with 15.3M shares traded, and some observers are watching for a push toward the $2.27–$2.36 zone if it can hold above VWAP.
Telomir Pharmaceuticals' discovery that Telomir-1 selectively kills aggressive triple-negative breast cancer cells is being seen as a major breakthrough, with some analysts noting its potential to expand across aging, oncology, and epigenetics.

Newcomers· Nov 21

The newcomer is excited about Telomir Pharmaceuticals' ($TELO) pre-market surge due to strong data catalysts, with a target price of $1.50-$2.00 and a stop loss at $1.30.
The newcomer is impressed by the company's announcement of new preclinical data showing Telomir-1 induces dose-dependent cell death in HL60 leukemia cells, expanding its oncology profile.
The newcomer is cautiously optimistic about $TELO's potential, noting that it has had great PR's but only seen small gains, and speculating that a big gain might come with an acquisition or significant volume.

Generated by AI

Findings Strengthen Telomir-Zn’s Oncology-Focused Platform While Demonstrating Broader Relevance of Its Metal-Dependent Epigenetic BiologyMIAMI, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, today announced the peer-reviewed publication of new preclinical research showing that Telomir-Zn significantly improved visual function, rest

12d agoYahoo Finance

Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models

1mo agoYahoo Finance

Also Discussed

Investors talking about TELO also mention

#	Name	Attention
1	Calidi Biotherapeutics, Inc.CLDI	0%0
2	BSLK - Bolt Projects Holdings, Inc.	——
3	Bbb Foods Inc.TBBB	0%+0
4	IceCure Medical Ltd.ICCM	0%0
5	Intapp Inc.INTA	0%0
6	Polestar Automotive Holding UK PLCPSNYW	0.01%+0.01
7	nCino, Inc.NCNO	0%0
8	PureCycle Technologies Inc.PCT	0%+0
9	Keurig Dr Pepper Inc.KDP	0%+0
10	PBF Energy Inc.PBF	0%0

Telomir Pharmaceuticals, Inc.

Healthcare
Biotechnology

Telomir Pharmaceuticals, Inc. is a preclinical-stage biotechnology company focused on developing small-molecule therapeutics designed to address the biological drivers of aging and age-related diseases. Its lead program centers on Telomir-1, an oral small molecule being studied for its ability to regulate metal ions and support cellular processes linked to telomere maintenance, epigenetic control, and inflammatory pathways. The company’s research spans a range of therapeutic areas, including oncology, metabolic disorders, ophthalmology, and neurodegenerative conditions. Telomir Pharmaceuticals, Inc. positions its platform around targeting underlying mechanisms rather than isolated symptoms, with current work aimed at advancing therapies for conditions such as triple-negative breast cancer, Wilson’s disease, type 2 diabetes, age-related macular degeneration, Alzheimer’s disease, and Progeria. The company is headquartered in Tampa, Florida.

Website

Location

100 SE 2nd Street

Miami, FL, 33131

United States

Social

What share of all stock conversation is about TELO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Apr 30

Telomir Pharmaceuticals' ($TELO) IND for Telomir-Zn in triple-negative breast cancer has been cleared by the FDA, allowing for a Phase 1/2 clinical trial to begin in the first half of 2026.
The trial, TELO-001, will evaluate Telomir-Zn as an oral monotherapy in approximately 76 patients who have previously undergone systemic treatment, focusing on safety, tolerability, and early signs of efficacy.
The company has acquired TELI Pharmaceuticals, establishing global ownership rights to Telomir-1, and has received $1M in funding, aligning with clinical milestones.

Generated by AI

Sentiment

Of the messages about TELO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	66.67% +57.78	64.53% -5.21
Bearish	—	0% 0	33.33% -57.78	35.47% +5.21

Bullish· Nov 21

$TELO is surging pre-market on strong data catalysts, with a key breakout level at $1.43 and a target of $1.50-$2.00.
Telomir Pharmaceuticals has published several high-quality articles in the past five months to build shareholder value, including a recent article about their flagship drug Telomir-1 and its potential for leukemia treatment.
$TELO has a low float and high short interest, making it a potential candidate for a big move when good news is announced, with some speculators predicting a run up to $1.80.

Bearish· Nov 21

The market is treating Telomir Pharmaceuticals with disrespect despite positive news, such as life-saving results for blood cancer.
Short sellers are consistently winning in the market, and the company's positive press releases are often followed by a brief spike and then destruction of the stock price.
The company's recent price action is likely due to dilution, delisting, or reverse splitting, which can be indicative of a scam or fraudulent activity, according to the author.

Generated by AI

Topics

Of the messages about TELO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	73.24%
Analysts	—	—	0%	0.38%
Controversies	—	—	0%	8.58%
Earnings	—	—	0%	0.51%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	17.29%

Announcements· Oct 21

Telomir Pharmaceuticals has executed a binding Letter of Intent (LOI) to acquire TELI Pharma, unifying global rights to Telomir-1 cancer and aging therapy.
The deal positions the company for global market expansion and value growth, with up to $5 million in milestone-tied shareholder contributions.
The acquisition grants Telomir Pharmaceuticals worldwide control of Telomir-1, with a potential $5 million milestone payment, and is seen as a significant upgrade to the company's pipeline.

Technical Analysis· Oct 9

$TELO is breaking down toward $2.05 support after forming a double top near $2.30, with momentum shifting below VWAP and the 9 EMA.
The stock has a strong technical rebound after bouncing off the 0.786 Fib zone near $2.03 and reclaiming 0.618 at $2.13, with a sharp e recovery.
$TELO is showing a potential breakout over $2.20 resistance on the daily chart, with a high volume of 9.5M shares and a low float of 12.97M, setting the stage for volatility.

Generated by AI

Community

Of the messages about TELO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	51.72%	48.36%
Newcomers	—	0%	48.28%	51.64%

Regulars· Oct 9

$TELO is setting up for a strong open after premarket gains, with some analysts highlighting its potential to "go ballistic".
The stock's volume is increasing, with 15.3M shares traded, and some observers are watching for a push toward the $2.27–$2.36 zone if it can hold above VWAP.
Telomir Pharmaceuticals' discovery that Telomir-1 selectively kills aggressive triple-negative breast cancer cells is being seen as a major breakthrough, with some analysts noting its potential to expand across aging, oncology, and epigenetics.

Newcomers· Nov 21

The newcomer is excited about Telomir Pharmaceuticals' ($TELO) pre-market surge due to strong data catalysts, with a target price of $1.50-$2.00 and a stop loss at $1.30.
The newcomer is impressed by the company's announcement of new preclinical data showing Telomir-1 induces dose-dependent cell death in HL60 leukemia cells, expanding its oncology profile.
The newcomer is cautiously optimistic about $TELO's potential, noting that it has had great PR's but only seen small gains, and speculating that a big gain might come with an acquisition or significant volume.

Generated by AI

Telomir Pharmaceuticals

Social

Apr 30

Sentiment

Bullish· Nov 21

Bearish· Nov 21

Topics

Announcements· Oct 21

Technical Analysis· Oct 9

Community

Regulars· Oct 9

Newcomers· Nov 21

News

Telomir announces preclinical study on AMD treatment candidate

Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD)

Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models

Also Discussed

Telomir Pharmaceuticals, Inc.

Company Information

Location

News

Telomir announces preclinical study on AMD treatment candidate

Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD)

Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models

Also Discussed

Social

Apr 30

Sentiment

Bullish· Nov 21

Bearish· Nov 21

Topics

Announcements· Oct 21

Technical Analysis· Oct 9

Community

Regulars· Oct 9

Newcomers· Nov 21